Twelve of 16 (75%) supraventricular tachycardias were abruptly terminated by intravenously administered edrophonium chloride (Tensilon) in doses ranging from 5 to 20 mg. Transient side effects of the drug were seen in five patients (31.3%) and subsided spontaneously as the drug effect was rapidly dissipated. The experience of other investigators is reviewed and the mechanism of drug action is discussed. Despite little recognition to date as an antiarrhythmic agent, edrophonium may prove to be the initial drug treatment of choice in managing a variety of supraventricular tachyarrhythmias.
Cantwell JD, Dawson JE, Fletcher GF. Supraventricular Tachyarrhythmias: Treatment With Edrophonium. Arch Intern Med. 1972;130(2):221–224. doi:10.1001/archinte.1972.03650020051009
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: